Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom

Seizure : the Journal of the British Epilepsy Association
Lara Verdian, Yunni Yi

Abstract

To estimate the cost-effectiveness of rufinamide relative to topiramate and lamotrigine as adjunctive treatment for children with Lennox-Gastaut Syndrome (LGS). A Markov decision analytic model was developed to estimate the incremental cost-effectiveness ratio over a three-year time horizon in patients with LGS uncontrolled by up to three antiepileptic drugs. Utilities were assigned to health states, defined according to a patient's response to treatment (> or =75%, > or =50% and <75%, and <50% reduction in tonic-atonic [drop attack] seizure frequency and death). Efficacy and safety estimates were made using indirect/mixed-treatment comparisons of data obtained from published literature. Outcomes included costs and quality-adjusted life-years (QALYs), allowing the incremental cost-effectiveness ratio to be estimated as cost per QALY gained. Over three years, the total cumulative costs for rufinamide, topiramate, and lamotrigine were pound24,992, pound23,360, and pound21,783, respectively. Rufinamide resulted in an incremental QALY gain of 0.079 relative to topiramate and 0.021 relative to lamotrigine. The incremental costs of rufinamide were pound1632 and pound3209, relative to topiramate and lamotrigine, resulting in an increm...Continue Reading

References

Oct 1, 1992·Clinical EEG (electroencephalography)·L F FitzgeraldL L Lansky
Apr 29, 1998·European Journal of Clinical Pharmacology·A MessoriG Zaccara
Mar 8, 1998·PharmacoEconomics·A Briggs, M Sculpher
Dec 1, 1999·Annals of the Rheumatic Diseases·C Bombardier, A Maetzel
Oct 14, 2000·Journal of Neurology, Neurosurgery, and Psychiatry·P J ThompsonJ W Sander
Oct 24, 2001·Epilepsy Research·S Arroyo, A de la Morena
Jun 13, 2002·Epilepsia·Peter Camfield, Carol Camfield
Sep 13, 2002·Acta Neurologica Scandinavica·A GubermanUNKNOWN EPAJ-119 Study Group
Jul 24, 2004·BMJ : British Medical Journal·Michael D Rawlins, Anthony J Culyer
Jul 15, 2005·Health Technology Assessment : HTA·A M GlennyUNKNOWN International Stroke Trial Collaborative Group
Sep 9, 2005·Acta Neurologica Scandinavica·S ArroyoUNKNOWN EPMN-106/INT-28 Investigators
Aug 5, 2006·Epilepsia·Albert P Aldenkamp, Willem C J Alpherts
Nov 1, 2006·International Journal of Clinical Practice·A Cheng-HakimianJ W Miller
Dec 13, 2006·Seizure : the Journal of the British Epilepsy Association·Emma J FrewStirling Bryan
Jan 20, 2007·International Journal of Technology Assessment in Health Care·Michael F DrummondJoan Rovira
Jan 30, 2007·Biological Psychiatry·Susan L McElroyUNKNOWN Topiramate Binge Eating Disorder Research Group
Feb 12, 2008·Seizure : the Journal of the British Epilepsy Association·G ZaccaraM Cincotta
Apr 11, 2008·International Journal of Technology Assessment in Health Care·Gerald Gartlehner, Charity G Moore
May 21, 2008·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Jeroen P JansenWiro Stam
May 30, 2008·Frontiers in Bioscience : a Journal and Virtual Library·Jennifer R O'Hara, Andre G Buret

❮ Previous
Next ❯

Citations

Feb 16, 2013·Acta Neurologica Scandinavica·J A CramerC François
Jun 28, 2014·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Nick AdlardEmma Frew
Feb 26, 2011·Expert Opinion on Pharmacotherapy·Frank M C Besag
Aug 27, 2013·Epilepsy & Behavior : E&B·Karen M ClementsAmy K O'Sullivan
Jan 19, 2017·Epilepsia·Ben F M WijnenReina J A de Kinderen
Nov 19, 2013·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Leslie WilsonSandy Srinivas
May 15, 2020·PharmacoEconomics·Jesse ElliottDoug Coyle

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.